? VDDRC PILOT AND FEASIBILITY PROGRAM The Pilot and Feasibility (P/F) Program is a vital, essential component of the Vanderbilt DDRC (VDDRC). It directly supports the overall goals of the VDDRC, which are to: 1) promote digestive diseases research in an integrative, collaborative, and multidisciplinary manner; 2) attract new investigators to the study of these disorders; 3) enhance the innovative research capabilities of members; and 4) promote the career development of junior investigators. Through the P/F Program, we have a strong track record of recruiting highly talented young investigators and established investigators that are new to digestive disease research, as well as established GI investigators testing exciting new ideas. In the past 10 years, we have supported 58 P/F recipients, with 27 of these in the past 5 years. Our number of grants and the amount of support is greatly enhanced by a commitment of $100,000 per year from VUMC, plus additional funding available from the Vanderbilt Institute for Clinical and Translational Research (VICTR, Vanderbilt CTSA). Over the past two grant award cycles (years 6-15), P/F recipients have garnered $47,707,648 in Direct Cost funding subsequent to their P/F awards, yielding a 30? fold return on investment of the NIH funds used for P/F awards. We have demonstrated major benefits to the career development of PIs that were supported as Type N (New Investigators) in the P/F program, including development of faculty as transformers of their research fields and growth into academic leadership positions. The P/F Program has been directed since 2010 by Keith T. Wilson, M.D., Thomas F. Frist Sr. Professor of Medicine, Cancer Biology, and Pathology, Microbiology and Immunology, and Associate Director of the VDDRC. The VDDRC provides an applicant-friendly environment in which annual P/F grant opportunities are widely circulated via the VDDRC website and email announcements, and potential candidates interact directly with the P/F Director to ensure that their projects meet the goals of the VDDRC, optimize use of VDDRC Cores, and meet NIH guidelines for rigor and reproducibility.
Our Specific Aims are: 1) To recruit talented New Investigators (Type N) without current or past independent NIH support to digestive disease research, in order to provide a foundation for career development and future independent funding; all successful Type N recipients benefit from enrollment in the VDDRC Academy of Investigators. 2) To recruit established investigators new to digestive disease research (Type EN), by supporting their studies of a digestive disease- related problem, with the goal of fostering collaborations and new directions that may lead to subsequent related publications, projects, and research grants in the field. 3) To support established investigators (Type E) in the digestive disease field in the pursuit of highly innovative, exciting new ideas, which is a significant departure from their previous work, and is likely to result in an important and fruitful new line of investigation. The overall goal is enhanced digestive disease-related research with exciting and transformative new ideas that can be catalyzed by P/F support and extensive interaction with Center members and activities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK058404-18
Application #
9710652
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
18
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Kohl, Kevin D; Dearing, M Denise; Bordenstein, Seth R (2018) Microbial communities exhibit host species distinguishability and phylosymbiosis along the length of the gastrointestinal tract. Mol Ecol 27:1874-1883
Kook, Seunghyi; Qi, Aidong; Wang, Ping et al. (2018) Gene-edited MLE-15 Cells as a Model for the Hermansky-Pudlak Syndromes. Am J Respir Cell Mol Biol 58:566-574
Sierra, Johanna C; Asim, Mohammad; Verriere, Thomas G et al. (2018) Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 67:1247-1260
Nyhoff, Lindsay E; Clark, Emily S; Barron, Bridgette L et al. (2018) Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages. J Immunol 200:2352-2361
West, Kathryn L; Kelm, Nathaniel D; Carson, Robert P et al. (2018) Myelin volume fraction imaging with MRI. Neuroimage 182:511-521
Harris, Nicholas A; Isaac, Austin T; Günther, Anne et al. (2018) Dorsal BNST ?2A-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors. J Neurosci 38:8922-8942
Rohrbough, Jeffrey; Nguyen, Hong-Ngan; Lamb, Fred S (2018) Modulation of ClC-3 gating and proton/anion exchange by internal and external protons and the anion selectivity filter. J Physiol 596:4091-4119
McDonnell, Wyatt J; Koethe, John R; Mallal, Simon A et al. (2018) High CD8 T-Cell Receptor Clonality and Altered CDR3 Properties Are Associated With Elevated Isolevuglandins in Adipose Tissue During Diet-Induced Obesity. Diabetes 67:2361-2376
Schlegel, Cameron; Lapierre, Lynne A; Weis, Victoria G et al. (2018) Reversible deficits in apical transporter trafficking associated with deficiency in diacylglycerol acyltransferase. Traffic 19:879-892
Shen, Xi; Liu, Liping; Peek, Richard M et al. (2018) Supplementation of p40, a Lactobacillus rhamnosus GG-derived protein, in early life promotes epidermal growth factor receptor-dependent intestinal development and long-term health outcomes. Mucosal Immunol 11:1316-1328

Showing the most recent 10 out of 1365 publications